Publicaciones en las que colabora con RAFAEL RODRIGUEZ PUERTAS (29)

2023

  1. Cannabinoids and endocannabinoid signaling at the basal forebrain cholinergic system

    Cannabis Use, Neurobiology, Psychology, and Treatment (Elsevier), pp. 417-430

  2. Mass Spectrometry for the Advancement of Lipid Analysis in Alzheimer’s Research

    Methods in Molecular Biology (Humana Press Inc.), pp. 245-259

  3. Microarrays, Enzymatic Assays, and MALDI-MS for Determining Specific Alterations to Mitochondrial Electron Transport Chain Activity, ROS Formation, and Lipid Composition in a Monkey Model of Parkinson’s Disease

    International Journal of Molecular Sciences, Vol. 24, Núm. 6

  4. Neuroanatomical characterization of the G protein-coupled receptor activity evoked by galanin-related ligands

    Journal of Chemical Neuroanatomy, Vol. 128

2022

  1. Cannabinoid Receptors and Glial Response Following a Basal Forebrain Cholinergic Lesion

    ACS Pharmacology and Translational Science, Vol. 5, Núm. 9, pp. 791-802

  2. Handling and novel object recognition modulate fear response and endocannabinoid signaling in nucleus basalis magnocellularis

    European Journal of Neuroscience, Vol. 55, Núm. 6, pp. 1532-1546

2021

  1. Chronic central modulation of LPA/LPA receptors-signaling pathway in the mouse brain regulates cognition, emotion, and hippocampal neurogenesis

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 108

  2. Modulation of neurolipid signaling and specific lipid species in the triple transgenic mouse model of alzheimer’s disease

    International Journal of Molecular Sciences, Vol. 22, Núm. 22

  3. Specific Phospholipid Modulation by Muscarinic Signaling in a Rat Lesion Model of Alzheimer's Disease

    ACS Chemical Neuroscience, Vol. 12, Núm. 12, pp. 2167-2181

2020

  1. Lisofosfolipidoen eta Alzheimer gaixotasunaren arteko erlazioa: etorkizuneko itu farmakologikoaren bila.

    Ekaia: Euskal Herriko Unibertsitateko zientzi eta teknologi aldizkaria, Núm. 38, pp. 55-71

  2. Neuropeptides and neurolipids: What they are and how they relate to Alzheimer’s disease

    Genetics, Neurology, Behavior, and Diet in Dementia: The Neuroscience of Dementia, Volume 2 (Elsevier), pp. 423-439

  3. Neurotransmitter receptors in Alzheimer’s disease: From glutamatergic to cholinergic receptors

    Genetics, Neurology, Behavior, and Diet in Dementia: The Neuroscience of Dementia, Volume 2 (Elsevier), pp. 441-456

2019

  1. CB1 and LPA1 Receptors Relationship in the Mouse Central Nervous System

    Frontiers in Molecular Neuroscience, Vol. 12

2018

  1. Endocannabinoid and Muscarinic Signaling Crosstalk in the 3xTg-AD Mouse Model of Alzheimer's Disease

    Journal of Alzheimer's Disease, Vol. 64, Núm. 1, pp. 117-136

  2. Re-examining the potential of targeting ABHD6 in multiple sclerosis: Efficacy of systemic and peripherally restricted inhibitors in experimental autoimmune encephalomyelitis

    Neuropharmacology, Vol. 141, pp. 181-191

  3. Selective up-regulation of cannabinoid CB1 receptor coupling to Go-proteins in suicide victims with mood disorders

    Biochemical Pharmacology, Vol. 157, pp. 258-265

2017

  1. Imaging mass spectrometry (IMS) of cortical lipids from preclinical to severe stages of Alzheimer's disease

    Biochimica et Biophysica Acta - Biomembranes, Vol. 1859, Núm. 9, pp. 1604-1614

  2. Increase in cortical endocannabinoid signaling in a rat model of basal forebrain cholinergic dysfunction

    Neuroscience, Vol. 362, pp. 206-218

  3. Lipid mapping of the rat brain for models of disease

    Biochimica et Biophysica Acta - Biomembranes, Vol. 1859, Núm. 9, pp. 1548-1557

2016

  1. Activity of muscarinic, galanin and cannabinoid receptors in the prodromal and advanced stages in the triple transgenic mice model of Alzheimer's disease

    Neuroscience, Vol. 329, pp. 284-293